Status:
WITHDRAWN
Middle Meningeal Artery Embolization for Chronic Subdural Hematoma
Lead Sponsor:
Washington University School of Medicine
Conditions:
Chronic Subdural Hematoma
Eligibility:
All Genders
18+ years
Brief Summary
Endovascular middle meningeal artery (MMA) embolization is an emerging treatment for chronic subdural hematoma (cSDH). There is preliminary data to suggest that this minimally invasive therapy may be ...
Detailed Description
This study seeks to assess the safety and efficacy of middle meningeal artery embolization for chronic subdural hematoma in addition to standard treatments, which include close observation and surgica...
Eligibility Criteria
Inclusion
- Patients 18 years or older undergoing treatment for a new diagnosis of chronic subdural hematoma (cSDH) or
- Patients 18 year or older who have undergone surgical evacuation of a subdural hematoma and have a significant residual hematoma status post-surgery or who develop a recurrent subdural hematoma.
- and
- Minimal symptoms such as headache, altered mental status, or mild neurological deficit only
- Ability to understand and sign written informed consent by patient or LAR
Exclusion
- Significant midline shift and/or neurologic symptoms requiring urgent decompression.
- Common carotid stenosis of over 50%.
- Significant contraindication to angiography (eg. kidney failure, difficult anatomy).
- SDH related to underlying condition
- Acute SDH
Key Trial Info
Start Date :
September 19 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2025
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04065113
Start Date
September 19 2019
End Date
June 1 2025
Last Update
July 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Washington University School of Medicine
St Louis, Missouri, United States, 63108